|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
13,640,000 |
Market
Cap: |
10.78(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.79 - $0.79 |
|
Level
I Sector: |
Industrials |
Level
II Sector: |
Diversified Services |
Level
III Sector: |
Business Services |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Sonnet BioTherapeutics Holdings is a clinical-stage biopharmaceutical company with a proprietary technology for developing biologic medicines it refers to as FHAB (Fully Human Albumin Binding). Co. has a pipeline of therapeutic compounds focused primarily on oncology indications of unmet medical need, including SON-080, a low-dose formulation of Interleukin 6 which is in development for Chemotherapy Induced Peripheral Neuropathy; SON-1010, which is being developed for solid tumor indications, including non-small cell lung cancer and head and neck cancer, as well as for antiviral applications; and SON-1210, which is being developed for solid tumor indications, including colorectal cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
50,000 |
539,855 |
Total Buy Value |
$0 |
$0 |
$0 |
$141,650 |
Total People Bought |
0 |
0 |
2 |
5 |
Total Buy Transactions |
0 |
0 |
2 |
7 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Mohan Pankaj |
Chairman, President and CEO |
|
2023-10-27 |
4 |
B |
$0.00 |
$0 |
D/D |
34,375 |
59,526 |
2.73 |
- |
|
Rao Raghu |
Director |
|
2023-10-27 |
4 |
B |
$0.00 |
$0 |
D/D |
15,625 |
16,813 |
2.31 |
- |
|
Markey John |
10% Owner |
|
2023-08-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
186,430 |
|
- |
|
Dexter Susan |
Chief Technical Officer |
|
2023-06-14 |
4 |
B |
$0.70 |
$7,000 |
D/D |
10,000 |
33,667 |
2.74 |
- |
|
Dyrness Albert D. |
Director |
|
2023-05-30 |
4 |
B |
$0.47 |
$10,883 |
D/D |
23,255 |
28,962 |
2.39 |
- |
|
Bhatt Nailesh |
Director |
|
2023-05-17 |
4 |
B |
$0.23 |
$5,800 |
D/D |
25,000 |
30,733 |
2.39 |
- |
|
Mohan Pankaj |
Chairman, President and CEO |
|
2023-05-15 |
4 |
B |
$0.22 |
$82,867 |
D/D |
371,600 |
553,331 |
2.81 |
- |
|
Mohan Pankaj |
Chairman, President and CEO |
|
2023-03-15 |
4 |
B |
$0.59 |
$35,100 |
D/D |
60,000 |
181,731 |
2.81 |
- |
|
Cross John Harry Iii |
Chief Financial Officer |
|
2023-02-06 |
4 |
D |
$1.06 |
$2,078 |
D/D |
(1,960) |
23,927 |
|
- |
|
Griffith Donald J. |
Director |
|
2023-02-06 |
4 |
D |
$1.04 |
$518 |
D/D |
(497) |
10,301 |
|
- |
|
Kenney Richard T |
Chief Medical Officer |
|
2023-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
14,627 |
18,198 |
|
- |
|
Kenney Richard T |
Chief Medical Officer |
|
2023-01-07 |
4 |
D |
$0.00 |
$0 |
D/D |
(14,627) |
3,571 |
|
- |
|
Cini John K. |
Chief Scientific Officer |
|
2023-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
18,551 |
40,271 |
|
- |
|
Cini John K. |
Chief Scientific Officer |
|
2023-01-07 |
4 |
D |
$0.00 |
$0 |
D/D |
(18,551) |
21,720 |
|
- |
|
Mohan Pankaj |
Chairman, President and CEO |
|
2023-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
73,561 |
121,731 |
|
- |
|
Mohan Pankaj |
Chairman, President and CEO |
|
2023-01-07 |
4 |
D |
$0.00 |
$0 |
D/D |
(73,561) |
48,170 |
|
- |
|
Dexter Susan |
Chief Technical Officer |
|
2023-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
14,627 |
23,667 |
|
- |
|
Dexter Susan |
Chief Technical Officer |
|
2023-01-07 |
4 |
D |
$0.00 |
$0 |
D/D |
(14,627) |
9,040 |
|
- |
|
Dyrness Albert D. |
Director |
|
2022-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
3,770 |
30,893 |
|
- |
|
Rao Raghu |
Director |
|
2022-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
3,770 |
26,140 |
|
- |
|
Mohan Pankaj |
Chairman, President and CEO |
|
2022-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
74,205 |
748,606 |
|
- |
|
Cross John Harry Iii |
Chief Financial Officer |
|
2022-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
15,519 |
160,684 |
|
- |
|
Cini John K. |
Chief Scientific Officer |
|
2022-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
18,551 |
322,652 |
|
- |
|
Mcneill Lori |
Director |
|
2022-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
3,770 |
3,770 |
|
- |
|
Bhatt Nailesh |
Director |
|
2022-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
3,770 |
31,255 |
|
- |
|
168 Records found
|
|
Page 1 of 7 |
|
|